Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro

被引:135
作者
Ogura, H
Kosasa, T
Kuriya, Y
Yamanishi, Y
机构
[1] Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 30026, Japan
[2] UCL, Eisai London Res Labs Ltd, London, England
来源
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY | 2000年 / 22卷 / 08期
关键词
donepezil hydrochloride; tacrine; physostigmine; rivastigmine; TAK-147; ipidacrine; cholinesterase inhibitor; acetylcholinesterase; butyrylcholinesterase;
D O I
10.1358/mf.2000.22.8.701373
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was designed to compare the in vitro inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) of donepezil and some other cholinesterase (ChE) inhibitors which have been developed for the treatment of Alzheimers disease. The carbamate derivatives physostigmine and rivastigmine needed preincubation to exhibit appropriate anti-ChE activity. The maximum ChE inhibition by physostigmine developed within 30-60 min, while the inhibitory effect of rivastigmine on AChE and BuChE activities reached its peak after 48 and 6 h, respectively. The order of inhibitory potency (lC(50)) towards AChE activity under optimal assay conditions for each ChE inhibitor was: physostigmine (0.67 nM) > rivastigmine (4.3 nM) > donepezil (6.7 nM) > TAK-147 (12 nM) > tacrine (77 nM) > ipidacrine (270 nm). The benzylpiperidine derivatives donepezil and TAK-147 showed high selectivity for AChE over BuChE. The carbamate derivatives showed moderate selectivity, while the 4-aminopyridine derivatives tacrine and ipidacrine showed no selectivity. The inhibitory potency of these ChE inhibitors towards AChE activity may illustrate their potential in vivo activitiy. (C) 2000 Prous Science. All rights reserved.
引用
收藏
页码:609 / 613
页数:5
相关论文
共 33 条
[1]  
Anand R, 1996, J DRUG DEV CLIN PR, V8, P109
[2]  
BEERMANN B, 1993, ACTA NEUROL SCAND, V88, P53
[3]   NEUROTRANSMITTER-RELATED ENZYMES AND INDEXES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES [J].
BOWEN, DM ;
SMITH, CB ;
WHITE, P ;
DAVISON, AN .
BRAIN, 1976, 99 (SEP) :459-496
[4]   Huperzine A, a novel promising acetylcholinesterase inhibitor [J].
Cheng, DH ;
Ren, H ;
Tang, XC .
NEUROREPORT, 1996, 8 (01) :97-101
[5]  
CUADRA G, 1994, J PHARMACOL EXP THER, V270, P277
[6]  
DAVIES P, 1976, LANCET, V2, P1403
[7]   A NEW AND RAPID COLORIMETRIC DETERMINATION OF ACETYLCHOLINESTERASE ACTIVITY [J].
ELLMAN, GL ;
COURTNEY, KD ;
ANDRES, V ;
FEATHERSTONE, RM .
BIOCHEMICAL PHARMACOLOGY, 1961, 7 (02) :88-&
[8]  
ENZ A, 1993, PROG BRAIN RES, V98, P431
[9]   INVITRO PROTECTION OF ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE BY TETRAHYDROAMINOACRIDINE - COMPARISON WITH PHYSOSTIGMINE [J].
GALLI, A ;
MORI, F ;
GORI, I ;
LUCHERINI, M .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (11) :2427-2433
[10]   The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex [J].
Giacobini, E ;
Zhu, XD ;
Williams, E ;
Sherman, KA .
NEUROPHARMACOLOGY, 1996, 35 (02) :205-211